Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $660
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsPrice TargetHot
Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and lowers the price target from $665 to $660.
Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and lowers the price target from $665 to $660.